The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

Dive Insight: Merck KGaA’s proposed acquisition of SpringWorks is the first biotech buyout worth more than $1 billion to be announced since mid-January, when Johnson & Johnson agreed to purchase ...

Revenue Growth: SpringWorks Therapeutics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 1029.96%.

As the FDA mulls over SpringWorks’ experimental neurofibromatosis type 1 plexiform neurofibromas (NF1-PN) drug mirdametinib during its rolling submission, the biotech isn't wasting time in ...

Get the latest news on SpringWorks Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SWTX performance ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a commercial-stage biopharmaceutical company focusing on cancer and severe rare diseases. OGSIVEO (nirogacestat) is its FDA-approved therapy for ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is up 47.80% year-to-date. Overall, SWTX ranks 14th on our list of the biotech stocks that are skyrocketing so far in 2025.

SpringWorks Therapeutics Inc has a consensus price target of $55 based on the ratings of 9 analysts. The high is $77 issued by Wedbush on February 12, 2025.

SpringWorks Therapeutics' cash burn of US$67m is about 1.8% of its US$3.7b market capitalisation. That means it could easily issue a few shares to fund more growth, and might well be in a position ...

SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...

SpringWorks Therapeutics is planning to initiate a Phase 3 program to establish safety and efficacy of its MEK 1/2 inhibitor (PD-0325901) in the NF1 population and will work collaboratively with ...

Merck KGaA’s proposed acquisition of SpringWorks is the first biotech buyout worth more than $1 billion to be announced since mid-January, when Johnson & Johnson agreed to purchase Intra ...